Key Investor Signals
Secured £500,000 from Medicines Discovery Catapult
Medicines Discovery Catapult, a UK drug-discovery organisation, committed investment and scientific support for payload validation and nanoparticle delivery development.
CEO led Moderna cancer-vaccine technical development
Co-founder David Pajerowski led Phase I and Phase II technical development of Moderna's personalised cancer vaccine, bringing relevant experience in advancing investigational medicines.
Emerged from a Deep Science Ventures–AbbVie initiative
Venture builder Deep Science Ventures worked with drugmaker AbbVie to originate the immune-reprogramming concept and recruited founders to launch Flip.
Team
David Pajerowski
Co-founder, CEO and Head of Technology
- Held technology leadership roles at Repertoire Immune Medicines and Nvelop Therapeutics, developing investigational therapies.
- Worked in bioprocessing and manufacturing sciences at Merck, gaining experience in how biological medicines are produced.
- Led Phase I and Phase II technical development of Moderna’s personalised cancer vaccine programme.
Mathias Pawlak
Co-founder
- Led programmes and teams at BlueRock Therapeutics and Portal Biotechnologies, working in biotechnology research and development.
- Conducted PhD research with Rudolf Jaenisch at the Whitehead Institute/MIT, studying stem cell biology and reprogramming.
- Trained as a postdoctoral fellow with immunologist Vijay Kuchroo at Harvard Medical School and Brigham and Women's Hospital.
Anis Gammage
Co-founder
- Contributed to multiple biotech spinouts at Deep Science Ventures, a venture builder creating research-based companies.
- Supported immunology and epigenetic drug-development programmes at UCB Pharma and Boehringer Ingelheim.
- Scoped neurofibromatosis research with the Children's Tumor Foundation at Deep Science Ventures, identifying therapeutic bottlenecks.
Product
The platform combines mRNA payloads with lipid nanoparticle delivery to reprogram T cells directly inside the body. Flip is developing this approach for chronic autoimmune and inflammatory disease, with payload validation and delivery integration as current development priorities.
Reprogramming disease-driving T cells
Flip is developing payloads intended to change pathogenic T cells into anti-inflammatory cells. The approach aims to reduce the cells driving tissue damage while increasing local immune suppression.
Encoding the treatment in mRNA
The therapeutic instructions are encoded in mRNA. Flip uses this format to carry its proprietary reprogramming payloads, with the aim of changing how immune cells behave within the affected tissue.
Lipid nanoparticle delivery
Lipid nanoparticles carry the mRNA payloads into cells. Development work includes integrating the payloads with this delivery technology so that immune-cell reprogramming can take place directly in the body.
Market Overview
Immune-modulating medicines serve patients with chronic autoimmune and inflammatory diseases through specialist prescribing and health-system or insurer coverage. Established treatments control symptoms for many patients, but a substantial group still cycles through therapies without sustained remission.
This is a competitive prescription-drug market with established spending, expanding treatment options and lower-cost biosimilars. Payers weigh clinical benefit against existing therapies and budget impact. Demand for durable disease control coexists with access barriers for patients eligible for advanced treatment.
AbbVie’s immunology portfolio generated $30.406B in global net revenue in 2025.
The US represented about three-quarters of global immunology sales in IQVIA’s 2024 market analysis.
About 63% of eligible moderate-to-severe psoriasis patients in seven major markets had received no prior advanced therapy.
Ustekinumab biosimilars reached 33% of European treatment days within two quarters of launch.
Comparable Outcomes
Capstan Therapeutics
Capstan Therapeutics developed targeted lipid nanoparticles that deliver mRNA to engineer T cells inside the body. Its lead candidate was in Phase 1 for B cell-mediated autoimmune diseases. AbbVie completed the acquisition in August 2025, adding Capstan’s lead therapy and its platform for delivering RNA payloads to specific cells.
Interested in More Startups Like Flip Therapeutics?
Get a curated pipeline of healthcare and life sciences startups aligned with your investment thesis.
Sources
This profile was built from public company materials, ecosystem sources, market references, and professional profiles.